Form 4: Pfizer Director Dan R. Littman Acquires Phantom Stock Units

Pfizer Inc. director Dan R. Littman was granted 7,686.539 phantom stock units as part of the company's deferred compensation plan.

Summary

• Director Dan R. Littman acquired 7,686.539 phantom stock units on April 23, 2026.
• The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of common stock valued at $26.67 per unit.
• Following this transaction, the director's total beneficial ownership of phantom stock units is 74,533.568.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory filing regarding director compensation with no impact on company operations or financial strategy.

Positives

• Director alignment with company performance through equity-based compensation.
• Standardized deferred compensation structure for non-employee directors.

Negatives

• None identified.

Risks

• Value of phantom stock units is subject to the future market performance of Pfizer common stock.

Future Outlook

The units are settled in cash or common stock at the director's election following their retirement from the Board of Directors.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common among large-cap pharmaceutical companies to ensure board members maintain a long-term interest in shareholder value.

Comparison to Industry Standards

• The use of phantom stock units for director compensation is a standard practice among S&P 500 companies, including peers like Merck and Bristol Myers Squibb, to align director interests with long-term equity performance.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation arrangement.

Next Steps

• Settlement of units upon the director's future retirement from the Board.

Key Dates

Keywords

Pfizer, PFE, Form 4, Insider Trading, Director Compensation, Phantom Stock